CTNM

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Wall Street analysts forecast CTNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTNM is 24.00 USD with a low forecast of 20.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Contineum Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Contineum Therapeutics Inc. EPS for the last quarter amounts to -0.45 USD, increased 12.50 % YoY.

Contineum Therapeutics Inc (CTNM) has 41 emplpoyees as of December 15 2025.

Today CTNM has the market capitalization of 339.39M USD.